(Total Views: 632)
Posted On: 08/22/2020 11:56:25 AM
Post# of 154091
remdesivir was denied here are the findings:
https://jamanetwork.com/journals/jama/fullart...erm=082120
August 21, 2020
Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19
A Randomized Clinical Trial
Christoph D. Spinner, MD1; Robert L. Gottlieb, MD, PhD2; Gerard J. Criner, MD3; et alJosé
Question Does remdesivir provide a benefit on clinical status for patients hospitalized with moderate coronavirus disease 2019 (COVID-19) pneumonia?
Findings In this randomized, open-label, phase 3 trial that included 584 patients with moderate COVID-19,
the day 11 clinical status distribution measured on a 7-point ordinal scale was significantly better for those randomized to a 5-day course of remdesivir (median length of treatment, 5 days) compared with those randomized to standard care.
The difference for those randomized to a 10-day course (median length of treatment, 6 days) compared with standard care was not significantly different.
Meaning Hospitalized patients with moderate COVID-19 randomized to a 5-day course of remdesivir had a statistically significantly better clinical status compared with those randomized to standard care at 11 days after initiation of treatment,
but the difference was of uncertain clinical importance.
statistically significantly better but
the difference was of uncertain clinical importance.
https://jamanetwork.com/journals/jama/fullart...erm=082120
August 21, 2020
Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19
A Randomized Clinical Trial
Christoph D. Spinner, MD1; Robert L. Gottlieb, MD, PhD2; Gerard J. Criner, MD3; et alJosé
Question Does remdesivir provide a benefit on clinical status for patients hospitalized with moderate coronavirus disease 2019 (COVID-19) pneumonia?
Findings In this randomized, open-label, phase 3 trial that included 584 patients with moderate COVID-19,
the day 11 clinical status distribution measured on a 7-point ordinal scale was significantly better for those randomized to a 5-day course of remdesivir (median length of treatment, 5 days) compared with those randomized to standard care.
The difference for those randomized to a 10-day course (median length of treatment, 6 days) compared with standard care was not significantly different.
Meaning Hospitalized patients with moderate COVID-19 randomized to a 5-day course of remdesivir had a statistically significantly better clinical status compared with those randomized to standard care at 11 days after initiation of treatment,
but the difference was of uncertain clinical importance.
statistically significantly better but
the difference was of uncertain clinical importance.
(1)
(0)
